chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Minor chest pain start 22:30.  At 13:00 on 05/09, pain quickly Increased to Severe Chest pressure within 15 min .  EMS dispatched. Initially treated as possible heart attack with aspirin and nitro with no results. Pain stable and controlled in approx.  4 hrs with Morphine.   Acute Pericarditis diagnosed. Released 05/11 approx . 19:00 hr.  Follow up treatment with Ibuprofen and Mitigare.
Since Shot - Arm pain at injection site continues through today.  Most intense issues were Tuesday 24 hours post shot when I had more intense headaches and body aches.  SOB remained the same.  Tuesday evening, 35 hours post shot, I had chills and low grade fever 99.3.  Slept for 10 hours and fever was gone and hasn't returned.  Intensity of arm pain is diminished but still quite sore at actual injection site.  Headaches are not as intense as Tuesday but continue to fluctuate in intensity as they have for the past 3 months.
I26.99 ACUTE PULMONARY EMBOLISM 6/4/2022 CELLULITIS I26.99 ACUTE PULMONARY EMBOLISM 6/4/2022 POSTPROCEDURAL SUPERFICIAL INCISIONAL WOUND INFECTION, INIT I26.99 ACUTE PULMONARY EMBOLISM 6/4/2022 SEVERE OBESITY I26.99 ACUTE PULMONARY EMBOLISM 6/4/2022 NAUSEA AND VOMITING I26.99 ACUTE PULMONARY EMBOLISM 6/4/2022 PALLIATIVE CARE I26.99 ACUTE PULMONARY EMBOLISM 6/4/2022 NONTRAUMATIC ACUTE KIDNEY INJURY I26.99 ACUTE PULMONARY EMBOLISM 6/4/2022 OPEN WOUND OF RIGHT CHEST WALL, INIT
Developed a rash below the injection site that is fading in and out; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (Developed a rash below the injection site that is fading in and out) in a 21-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Cellulitis (prone to cellulitis). Concurrent medical conditions included Immune system disorder (medically fragile, has a weak immune system).    On 01-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Mar-2021, the patient experienced VACCINATION SITE RASH (Developed a rash below the injection site that is fading in and out). The patient was treated with CEFALEXIN (KEFLEX [CEFALEXIN]) for Adverse event, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE RASH (Developed a rash below the injection site that is fading in and out) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication was not provided.
Patient reported having an aura migraine the morning after receiving her vaccination. She had migraine medication and after taking it the pain went away after a short time. She then experienced numbness which affected the right side of her face, her right arm, and her right foot. Her mobility was not affected. It lasted for about four hours and then subsided.
This spontaneous report as received from a nurse practitioner refers to a female patient of unknown age. On an unknown dates the patient was vaccinated with a first and second doses of GARDASIL (lot numbers, doses, sites and routes of administration were not reported). On an unknown dates the patient experienced syncopal episodes after both 1st and 2nd dose of GARDASIL. The outcome of syncopal episodes was not reported. The relatedness between vaccination with GARDASIL and syncopal episodes was not reported. Additional information has been requested.
This spontaneous report as received from a certified medical assistant refers to a 64 year old female patient with no drug reactions/allergies. On 06-DEC-2013 the patient was inadvertently vaccinated with a dose of ZOSTAVAX (lot # J006156, exp. date: 30-AUG-2014, 0.65 ml, one dose) for prevention of shingles, intramuscularly rather than by subcutaneous route. Concomitant therapies included omeprazole (manufacture unknown), simvastatin (manufacturer unknown), enalapril maleate, amlodipine and ubidecarenone. On 06-DEC-2013, the patient experienced small bruise (hematoma) and swelling at the injection site. It was noted that the patient returned to the office because she had forgotten her prescription, and upon returning to the office the medical assistant examined the injection site area and the swelling had gone down. The patient sought medical attention, she was seen at physician's office. No treatment was given for the adverse events. No lab diagnostic studies were performed. The outcome of the events was reported as recovering. Casual relationship between the events and ZOSTAVAX was not reported. Additional information has been requested.
Low fever (lasted 2-3 hours on first afternoon) Severe chills and shaking (lasted from 10:00 pm to 3:00 am next day) General achiness (continuing) Left arm soreness (continuing)
Chest pain, left arm numbness, tingling, and heaviness cold feeling to fingers O2 sats 88% from 99% then reounded back to 99 Ativan 1mg tab  Aspirin 324mg
I got blood clots in my legs. I had pain in my legs for 7 days before I called my doctor. He told me to go to the hospital which I did. They did an ultrasound and found the clots and referred my to a vascular surgeon. I waited for the clots to dissolve and have subsequently had the veins treated and/or removed in January and February of 2022.
the  tech gave me a shot the pain was so intense and gave bad pain down my arm and have numbness in my fingers. EMS at the site advised me to watch for potential hematoma and to go home and take tynelol and call primary physcian, Few hours passed pain persisted went to see a doctor she examined my arm and stated it is very possible that the she hit a nerve in my arm. She advised me to report  this and to go back to the facility to report to supervisor. I went back to facility they advised to report on line and eventually it will feel better.
The adult patients received pediatric (NDC 80777-279-05) Moderna COVID-19 vaccine with blue cap and label with Magenta border, as First primary dose 0.5ml to each patient.; This spontaneous case was reported by a pharmacist and describes the occurrence of INCORRECT DOSE ADMINISTERED (The adult patients received pediatric (NDC 80777-279-05) Moderna COVID-19 vaccine with blue cap and label with Magenta border, as First primary dose 0.5ml to each patient.) in an 18-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AS14146B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 30-Jun-2022, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 30-Jun-2022, the patient experienced INCORRECT DOSE ADMINISTERED (The adult patients received pediatric (NDC 80777-279-05) Moderna COVID-19 vaccine with blue cap and label with Magenta border, as First primary dose 0.5ml to each patient.). At the time of the report, INCORRECT DOSE ADMINISTERED (The adult patients received pediatric (NDC 80777-279-05) Moderna COVID-19 vaccine with blue cap and label with Magenta border, as First primary dose 0.5ml to each patient.) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication were provided.  NDC  number was reported as 80777-279-05.  No treatment details were provided
Oth complications following immunization, NEC, init on 2016-07-06.
MACUOLOPAPULAR RASH, STARTED ON LEFT ARM (SAME ARM AS INJECTION SITE, BUT MORE DISTAL) AND SPREAD TO RIGHT ARM, NECK, BACK, TRUNK, THIGHS.  ONSET TIME WAS THE EVENING AFTER RECEIVING IT (HOURS).  RASH MILDLY PRURITIC.  NO SYSTEMIC SYMPTOMS.  ANTIHISTAMINES PRESCRIBED.  PATIENT ADVISED TO CALL IF RASH OR SYMPTOMS WORSEN.
On approximately 10/19/2000, the patient had strep throat. On approximately 11/02/2000, the patient developed very mild chicken pox with approximately 20-30 lesions and no other symptoms. Lab tests revealed a negative titer for the serium varicella virus antibody test. Additionally, it was reported that the patient had 2 brothers who also developed chicken pox. The patient's mother, who had no previous confirmed case of chicken pox, was vaccinated on 07/10/1995. At the time of this report the mother had not developed any lesions or other symptoms. Additional information has been requested.
Person administering second vaccine gave me Pfizer instead of Moderna.  So I have now had Moderna 1 and Pfizer as my 2nd.
PATIENT RECEIVED VACCINE BEFORE AGE OF ELIGIBILITY DURING THE TIME OF VACCINATION.
5 hours after injection my legs from the knee to the ankle joint became very itchy, I wrapped them both in a cool wet towel to keep the itching down. This lasted for 48 hours and then went away.
it seems like patient have vasovagal symptoms 5 minutes right after vaccinated. she was nauseated and  sweat and almost faint. she said that she has hard time breathing. WE gave her 0.3mg epinephrine then she is ok  and better. we called EMS over. and she is all fine after that. SHE did not need to go to hospital.
Round, red area about 3" wide, warm to touch x 48 but worse during 2nd day.
Patient was given vaccine formulation for 12 years of age and older even though patient is only 6
After the pt had left yesterday, 10/10/23 it was found that an error had taken place with the pts COVID vaccine administration. This CMA did not note that the vaccine vial was a multidose vial that needed to be diluted prior to administration. The pt received 0.3ml of the COVID vaccine without dilution. The lead clinic nurse along with our pharmacist were contacted. Per pharmacy the pt should not have any long term effects from this error. The pt may experience an increase in the typical side effects from any COVID vaccine. The pts mother was notified. A safe qual event will be completed. This will also be reported to vaers. Safe guards have been put in place to ensure this does not happen again. This standard procedure was discussed during our nursing huddle this morning, will be reported via email in the nursing huddle minutes and a note was placed in the injection room.    Pts mother had inquired to see if the pt needed to get the additional 2 doses. Per pharmacy it was stated the pt should receive the 2nd and 3rd doses as recommended. The reason being to prolong protection from COVID.    Mother denied any symptoms or adverse reactions.    Pfizer-BioTech COVID-19 vaccine. Lot # HH3252 EXP: 07/2024
bad flared up of rheumatoid arthritis; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of RHEUMATOID ARTHRITIS (bad flared up of rheumatoid arthritis) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced RHEUMATOID ARTHRITIS (bad flared up of rheumatoid arthritis) (seriousness criterion medically significant). At the time of the report, RHEUMATOID ARTHRITIS (bad flared up of rheumatoid arthritis) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       patient wasn't sure if it was the Moderna vaccine or not  No concomitant medications were reported   No treatment information was provided  Company Comment: This case concerns an unknown age and unknown gender patient with no relevant medical history, who experienced the unexpected event of rheumatoid arthritis. The event occurred unknown number of days after a dose of mRNA-1273 vaccine.  It is not clear from the source document whether this was a first or second dose. The rechallenge was unknown since there's not enough information to assess this in the source document. The benefit-risk relationship of the vaccine not affected by this report.; Sender's Comments: This case concerns an unknown age and unknown gender patient with no relevant medical history, who experienced the unexpected event of rheumatoid arthritis. The event occurred unknown number of days after a dose of mRNA-1273 vaccine.  It is not clear from the source document whether this was a first or second dose. The rechallenge was unknown since there's not enough information to assess this in the source document. The benefit-risk relationship of the vaccine not affected by this report.
Information has been received from a registered nurse concerning college-aged females who received Gardasil at her clinic.  The nurse reported that they all experienced pain upon injection as well as burning pain after receiving the vaccination.  The nurse found that the thinner patients experienced more pain.  There was pain resolution by the time the patients left the office or by the following day.  This is one of several reports received from the same source.  Additional information has been requested.
Patient developed COVID and is now hospitalized on 11L high flow oxygen, dexamethasone, and remdesivir.
1st dose felt a metallic taste in mouth. Not sure if related. Came on a day or 2 after first shot; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 32 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 14Apr2021 16:00 (Lot number: EW0161) at the age of 32 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Anemia" (unspecified if ongoing); "soy" (unspecified if ongoing); "pollen" (unspecified if ongoing); "tree nuts" (unspecified if ongoing); "stone fruit" (unspecified if ongoing). Concomitant medication(s) included: PROZAC; NUTRAFOL; MULTIVITAMIN & MINERAL. The following information was reported: DYSGEUSIA (non-serious) with onset 06May2021 23:45, outcome "recovered" (2021), described as "1st dose felt a metallic taste in mouth. Not sure if related. Came on a day or 2 after first shot". Therapeutic measures were not taken as a result of dysgeusia.  Additional Information: Patient did not take other vaccine in four weeks. Patient did not take other medication in two weeks. Patient had not covid tested post vaccination.  No follow-up attempts are possible. No further information is expected.
doses administered after more than 1 temperature excursion; doses administered after more than 1 temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (doses administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (doses administered after more than 1 temperature excursion) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 035C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Oct-2021 at 1:44 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. In 2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (doses administered after more than 1 temperature excursion). On 27-Oct-2021 at 1:44 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (doses administered after more than 1 temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (doses administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (doses administered after more than 1 temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant products were not provided.  Patient age was reported as 66.63 years.  It was reported that unknown number of patients were administered with vaccines that experienced more than 1 temperature excursion during 33 weeks in 2021. The HCP explained that each time a vial was put into a cooler, there was a period of time of 1 hour or 1 and half hour approximately, when the temperature data logger registered 34 or 35 degree F.  The excursion time on initial supply was 8A, 9A and 10 A, temperature was 32, vaccine was not frozen prior to administration. Vaccine moved to fridge on 29-Sep-2021 and moved to clinic on 22-OCT-2021. 1 vials were sent to the clinic. BUD date was 29-Sep-2021. Vials only punctured right before administration.  Vaccine was stored in Cooler 1 on 22-Oct-2021.   Treatment medications were not reported.
Shortness of breath; Congestion; Coughing up sputum/Cough; Fever; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (Shortness of breath), NASAL CONGESTION (Congestion), COUGH (Coughing up sputum/Cough) and PYREXIA (Fever) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 044A21A and 043B21A) for COVID-19 vaccination.     Concurrent medical conditions included Asthma. Concomitant products included ALBUTEROL [SALBUTAMOL] for an unknown indication.   On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 10-May-2021, the patient experienced DYSPNOEA (Shortness of breath), NASAL CONGESTION (Congestion), COUGH (Coughing up sputum/Cough) and PYREXIA (Fever). At the time of the report, DYSPNOEA (Shortness of breath), NASAL CONGESTION (Congestion), COUGH (Coughing up sputum/Cough) and PYREXIA (Fever) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: positive (Positive) Positive.         Patient would like donate plasma or whatever information needed to further research for Covid 19.
Patient admitted with worsening shortness of breath.  The patient was sick for about a week with sore throat, cough, shortness of breath, and hypoxia.
A month after receiving both doses of the COVID 19 vaccine I contracted the COVID virus after being exposed to someone who had it.
hard injection site; swollen injection site; warm injection site; feeling a bit heavy and weak as well; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE INDURATION (hard injection site), VACCINATION SITE SWELLING (swollen injection site), VACCINATION SITE WARMTH (warm injection site) and ASTHENIA (feeling a bit heavy and weak as well) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse reaction.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Jun-2021, the patient experienced VACCINATION SITE INDURATION (hard injection site), VACCINATION SITE SWELLING (swollen injection site), VACCINATION SITE WARMTH (warm injection site) and ASTHENIA (feeling a bit heavy and weak as well). At the time of the report, VACCINATION SITE INDURATION (hard injection site), VACCINATION SITE SWELLING (swollen injection site), VACCINATION SITE WARMTH (warm injection site) and ASTHENIA (feeling a bit heavy and weak as well) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Headache, fever 101.8, chills, aches, joint and muscle pain.
Flu-like sx ("similar to when taking INH plus RIFAMPIN") /p 1st dose vax givn AUG90-aches & pains being treated w/aspirin or Tylenol; sx persist- "still feels run down" one mo post vax; 12AUG90 went home felt nauseated, weak & sweat all day
Vaccine received on 22 April 2022 approximately 3 weeks later lesion noticed on lower right leg. Appointment made with PCM clinic and seen on 1 June 2022. Referral made to dermatology at time of PCM visit. Seen by dermatology 10 Aug 2022 with diagnosis of lichen aureus/capillaritis to torso and lower extremities. Dermatology prescribed eucrisa ointment, currently awaiting authorization for dispensing.  Lesions on-going. Per dermatologist, to return to clinic for biopsy (scraping) if no improvement with prescribed treatment.
This spontaneous report as received from a certified medical assistant refers to an unspecified number of patients of unknown age and gender. No information regarding the patients' medical history and concurrent conditions was provided. On unknown dates, the patients were vaccinated with improperly stored doses of M-M-R II injection, once, lot # L030162, expiration date: 11-AUG-2017, (dose, dose number, route of administration and injection site were not provided). There were no concomitant medications reported. It was stated that the vaccine underwent temperature excursions of 30 degrees Fahrenheit for 73 hours and 49 degrees Fahrenheit for 25 hours, respectively, that were captured using digital data logger. No adverse effects were reported. No product complaint (PQC) was involved. This is one of several reports received from the same reporter. Additional information has been received.
AM of 10/30/03 noted that injection site was very sore, hot to touch and swelling 7cm x 5cm. 5 days before swelling and soreness resolved.
This case was reported by a nurse via sales rep and described the occurrence of injection site erythema in a female patient who received SHINGRIX. In May 2018, the patient received SHINGRIX. In May 2018, less than a week after receiving SHINGRIX, the patient experienced injection site erythema, injection site tenderness, erythema of extremities and pain in arm. On an unknown date, the outcome of the injection site erythema and erythema of extremities were recovered/resolved and the outcome of the injection site tenderness and pain in arm were unknown. It was unknown if the reporter considered the injection site erythema, injection site tenderness, erythema of extremities and pain in arm to be related to SHINGRIX. Additional details were provided as follows: The age at the vaccination was not reported. The patient was administered SHINGRIX 6 days before the reporting date. The patient reported redness and tenderness at injection site and on arm 5 days after receiving the vaccine. The patient has had redness lasting about 7 days (discrepant information). Clarification had been requested for correct onset time and duration. The physician was not too concerned and she was following up with patient again on the reporting date. She would call back after connecting with the patient. The reporter agreed to be contacted for follow up.
This spontaneous report has been received from a nurse practitioner regarding a patient of unknown age and gender. The patient's concurrent condition, medical history and concomitant medications were not reported. On an unknown date, the patient was vaccinated VARIVAX dose 1, (dose, lot # and expiry date unknown). On 08-OCT-2012, the patient received improperly stored VARIVAX dose 2, from lot # 0610AE (dose, vaccination site, route, expiry date unknown). No adverse effects were reported. The reporter stated that inconsistencies in storage temperature were identified on extensive review and records. The reporter stated that vaccine was not thawed. The nurse practitioner reported that there was insufficient data to provide 100 percent assurance on vaccine stability. This is one of several reports received from the same reporter. Additional information has been requested.